Loading, Please Wait...
EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor meetings at two conferences in April: Stifel First Annual CNS Day and William Blair 3rd Annual Late-Stage Therapeutics Conference.
Stifel First Annual CNS Day
|Date:||Monday, April 1, 2019|
|Location:||The Four Seasons Hotel, Boston|
|Panel:||Future of Epilepsy Treatment|
|Participant:||Stephen J. Farr, President and Chief Executive Officer|
|Time:||3:35 PM Eastern Time / 12:35 PM Pacific Time|
|William Blair 3 rd Annual Late-Stage Therapeutics Conference|
|Date:||Thursday, April 4, 2019|
|Location:||Omni Berkshire Place, New York|
|Panel:||New Therapies for Epileptic Disorders|
|Participant:||Gail Farfel, Ph.D., Executive Vice President & Chief Development Officer|
|Time:||8:00 AM Eastern Time / 5:00 AM Pacific Time|
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s lead candidate, FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency; is awaiting an acceptance decision by the U.S. Food & Drug Administration; and is in development in Japan. For more information, visit www.zogenix.com.
Senior Director, Corporate Communications
Public Relations, Syneos Health
+1 (858) 449 9575 | email@example.com
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com